Search Results

Humhealth, a leading provider of innovative remote care solutions, has the capability to integrate with an advanced 4G Telehealth Gateway Hub and 4G vital monitoring devices.

yner-G BioPharma Group (Syner-G), a leading provider of integrated pharmaceutical science and regulatory consulting services to pharmaceutical and biotechnology clients

Syner-G BioPharma Group (Syner-G), a leading provider of integrated pharmaceutical science and regulatory consulting services to pharmaceutical and biotechnology clients

Tandem Diabetes Care, Inc. and Dexcom, Inc., announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully compatible with both the Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring Systems.

G1 Therapeutics, Inc. announced that the Company has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes as of the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets, Monday, July 1, 2024.

G1 Therapeutics, Inc. today announced the grant of inducement stock options exercisable for 4,650 shares of G1’s common stock and 2,400 restricted stock units (RSUs) to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”).

Jacobio Pharma, a clinical-stage oncology company focusing on undruggable targets, presented updated data of a KRAS G12C inhibitor glecirasib in combination with a SHP2 inhibitor in frontline non-small cell lung cancer patients harboring KRAS G12C mutation at the 2024 American Society of Clinical Oncology Annual Meeting as form of oral presentation.

G1 Therapeutics on Monday reported Phase III study results showing its drug Cosela did not demonstrate a statistically significant effect in overall survival in triple-negative breast cancer patients.